analySEEs Report: Antibiotic Marketing Plan for India and South Asian Market

December 12, 2018 | Author: Analysees Consulting Group | Category: Tablet (Pharmacy), Antibiotics, Drugs, Medicine, Clinical Medicine
Share Embed Donate


Short Description

Ciprofloxacin is an antibiotic of Fluoroquinolones group. Ciprofloxacin is the fifth largest generic in the total Pharm...

Description

analySEEs

2008

Marketing

Plan

Ciprofloxacin

www.analySEEs.co.uk

1.0

Market Summary

Ciprofloxacin is an antibiotic of Fluoroquinolones group. Ciprofloxacin is the fifth largest generic in the total Pharma market. At the same time this market is continuously growing. Almost all leading companies paid their deep concentration in this market and this generic market has become more competitive. The leading brand Ciprocin (SQA) enjoys 20% share of Ciprofloxacin market. On the other hand the second brand leader Neofloxin continuously is loosing its market share. For that reason they reduced the price of all strength of Neofloxin. After that almost all leading brands including Ciprocin have become available at reduced price. Introduction of powder for suspension form add new cherry to the Ciprofloxacin market. Consecutive introduction of Ciprofloxacin suspension by seven company and price reduction issue make a noise in Ciprofloxacin market. So to compete in the competition and to increase market share we are proposing two campaigns named “Ciprofloxacin Patron” and “Ciprofloxacin Idol”.

OVERVIEW OF THERAPEUTIC MARKET

Therapeutic Class/ Sub-class

2008

2007

2006

Val*

Sh%

Gr.%

Val*

Sh%

Gr.%

Val*

Sh%

Gr.%

Cephalosporins & Combs

3081

46

10

2802

43

9

2583

41

8

Fluoroquinolones

1651

24

4

1583

24

6

1489

24

14

Penicillins

1105

16

-12

1260

19

-6

1335

21

-4

Macrolides & Similar Types

566

8

12

504

8

6

474

7

9

Trimethoprim Combs

160

2

-21

203

3

-11

229

4

-21

Tetracyclines & Combs

143

2

-16

170

3

-7

183

3

-7

18

1

-3

19

0

-16

22

0

8

9

0

-28

13

0

-11

14

0

-21

11

0

-9

12

0

82

7

0

1

Aminoglycosides Chloramphenicols & Combs Other Antibiotics

Source: IMS 2 Q, 2008; Value in BDT million nd

www.analySEEs.co.uk 

OVERVIEW OF THERAPEUTIC MARKET BY MARKET SHARE (2008) 2%

8%

3%

16%

46%

24%

Cephalos porins & Combs

F luoroquinolones

Penicillins

M ac rolides & Sim ilar Ty pes

Trimet hoprim Com bs

Other Ant ibiot ics

Source: IMS 2nd Q, 2008

2.0

Year

2008

2007

2006

Leading players

Brand Name

Company Name

Position

*Value

Share (%)

Growth (%)

Ciprocin

Square

1st

195

19.24

-1.38

Neofloxin

Beximco

2 nd

103

10.11

-18.33

Flontin

Renata

3rd

70

6.92

4.17

Quinox

Eskayef

4th

63

6.20

17.10

Cipro-A

Acme

5th

55

5.41

-7.69

Ciprox

Opsonin

6th

44

4.32

2.18

Ciprocin

Square

1st

198

20.06

8.74

Neofloxin

Beximco

2 nd

126

12.74

-3.01

Flontin

Renata

3rd

67

6.83

12.35

Cipro-A

Acme

4th

59

6.02

7.75

Quinox

Eskayef

5th

54

5.45

-19.37

Ciprox

Opsonin

6th

43

4.35

0.63

Ciprocin

Square

1st

182

18.22

4.50

Neofloxin

Beximco

2 nd

130

12.97

39.01

Quinox

Eskayef

3 rd

67

6.67

9.79

Flontin

Renata

4th

60

6.00

1.63

Cipro-A

Acme

5th

55

5.52

4.47

www.anal SEEs.co.uk 

Maprocin

Orion

6 50 5.02 8.63 Source: IMS 2 Q, 2008; Value in BDT million th

nd

3.0

Competition

DIRECT COMPETITION

2008 Brand

2007

Company Value

Share (%)

Growth (%)

Value

Share (%)

Growth (%)

Ciprocin

Square

195

19

-1

198

20

9

Neofloxin

Beximco

103

10

-18

126

13

-3

Flontin

Renata

70

7

4

67

7

12

Quinox

Eskayef

63

6

17

54

5

-19

Cipro-A

Acme

55

5

-8

59

6

8

Ciprox

Opsonin

44

4

2

43

4

1

1,015

63

3

988

64

2

Ciprofloxacin

Source: IMS 2 Q, 2008; Value in BDT million nd

INDIRECT COMPETITION

Ciprofloxacin will compete indirectly with Levofloxacin, Gatifloxacin, Nalidaxic acid and Cefradine preparations of the market. 2008 Brand

2007

Company Value

Share (%)

Growth (%)

Value

Share (%)

Growth (%)

Levoxin

IAP

48

16.70

-31.81

70

26.16

35.87

Trevox

SQA

33

11.57

-4.10

34

12.89

72.41

Ovel

ATP

30

10.64

88.88

16

6.02

999

Evo

BXM

20

7.05

139.15

8

3.15

999

Levox

OPI

18

6.18

-54.13

38

14.39

15.90

285

17.79

6.83

267

17.25

55.70

Levofloxacin

Source: IMS 2 Q, 2008; Value in BDT million nd

www.analySEEs.co.uk 

2008 Brand

2007

Company Value

Share (%)

Growth (%)

Value

Share (%)

Growth (%)

Gati

SQA

18

20.20

178.94

7

25.60

999

Gatiflox

IAP

16

18.13

12.19

7

29.11

999

Gatlin

RTA

15

17.00

98.32

8

30.30

999

90

5.62

253.55

25

1.65

999

Gatifloxacin

Source: IMS 2 Q, 2008; Value in BDT million nd

2008 Brand

2007

Company Value

Share (%)

Growth (%)

Value

Share (%)

Growth (%)

Lebac

SQA

186

17.48

11.90

166

15.94

18.40

Sefrad

SA

176

16.55

-11.01

198

18.98

-11.67

Skcef

SK+f

120

11.27

2.64

117

11.20

2.42

Avlocef

ACI

56

5.32

-28.17

78

7.43

2.67

Cephran

OPI

26

2.48

1.59

26

2.49

-14.67

1065

49.55

2.05

1044

53.39

3.98

Cefradine

Source: IMS 2 Q, 2008; Value in BDT million nd

www.analySEEs.co.uk 

4.0

Product Definition

Therapeutic class

:

Flouroquinolones Flouroquinolones

Sub-therapeutic class

:

Oral Flouroquinolones Flouroquinolones

Dosage form

:

Tablet, Powder for Suspension

Generic name

:

Ciprofloxacin Hydrochloride USP

Mechanism of action:

The mode of action involves the inhibition of DNA gyrase and Topoisomerase II, which mediates the formation of supercoils of DNA. The process is necessary for  compacting the bacterial chromosomes within the cell and ultimately DNA synthesis is hampered. PRICE ANALYSIS

Brand Name

Company

Ciprocin

Square

Neofloxin

Beximco

Flontin

Reneta

Quinox

Eskayef

Floxabid

ACI

Dosage form

Tablet Tablet Tablet Tablet Tablet Tablet XR Tablet Tablet Tablet Powder for Susp Tablet Tablet Tablet Powder for Susp Tablet Tablet Tablet Powder for Susp

Strength

Pack  size

MRP/Tab (BDT)

250 mg Tab 500 mg Tab 750 mg Tab 250 mg Tab 500 mg Tab 750 mg Tab 500 mg XR Tab 250 mg Tab 500 mg Tab 250 mg/5 ml 250 mg Tab 500 mg Tab 750 mg Tab 250 mg/5 ml 250 mg tablet 500 mg tablet 750 mg tablet 250 mg/5 ml

10x3 10x2 10x2 10x5 10x4 10x3 10x2 10x2 10x3 60 ml 10x3 10x3 10x1 60 ml 10x5 10x3 10x2 60 ml

8.50 14.00 18.00 8.50 14.00 18.00 15.00 8.50 14.00 60.00 8.50 14.00 18.00 60.00 8.50 14.00 18.00 60.00

www.analySEEs.co.uk 

5.0

SWOT Analysis

Strengths •

The molecule of choice in the treatment of enteric infection.



Strong perception of all-rounder antibiotic.



All the possible dosage forms of Ciprofloxacin Ciprofloxacin are prescribed.

Weaknesses •

Reported side-effects. side-effects.



Expensive than Penicillins



Less effective than 3 and 4 generation Cephalosporins Cephalosporins rd

th

Opportunities •



Ciprofloxacin market is continuously growing and now holding the fifth highest selling molecule in Bangladesh Pharma Market. Specialist wise doctor’s promotion will be the new opportunity to maximize the market share.

Threats •



Strong brand focuses of the leading companies increase the competition in this generic market. Threatening growth of 3 and 4 generation Cephalosporins rd

th

www.analySEEs.co.uk 

6.0

Positioning

Ciprofloxacin – an all round protection against bacterial infections. Ciprofloxacin an ideal drug in the treatment of •

Enteric infections



Urinary tract infection



Gastrointestinal tract infections

Market Segmentation

Ciprofloxacin tablet can be promoted to the follow f ollowing ing doctors a. Doctors who prescribe p rescribe Ciprofloxacin Ciprofloxacin b. Doctors who prescribe Cephradine c. Doctors who prescribe Azithromycin for the treatment of enteric infection. Ciprofloxacin powder powder for suspension will be promoted to the following doctors a. Doctors who prescribe Erythromycin suspension b. Doctors who who prescribe Azithromycin Azithromycin suspension suspension c. Doctors who who prescribe Cephradine Cephradine suspension suspension d. Doctors who prescribe prescribe Nalidixic Nalidixic Acid suspension Target Doctors Doctor Categories

General Practitioners Gynecologists Pediatricians Medicine Medicine specialists Gastroenterologists Surgeons Internee Doctors

www.analySEEs.co.uk 

7.0

C o m m u n i c a t i on s t r a t e g i e s

No. of Detailing Promotions

:

06

No. of Reminder Promotions

:

12

No. of Clinical Meeting

:

03

Gifts / Special Campaigns Campaigns

:

03

Promotional Campaigns Campaign-01

1.

Objective: •

2.

To establish Ciprofloxacin as the drug of choice in the treatment tre atment of UTI

Activities: •



Special promotion highlighting Urinary tract infection to selective six hundreds gynecologist. Reminder promotion to make extra thirst to other target doctors.

3

Duration: January to April 2008

4.

Cycle Promotion

Promotion Detailing Reminder Gifts 5.

Target doctors:

January √ √

Month February March √ √ √ √

April √

Gynecologists General Practitioners Medicine specialists Gastroenterologists Internee Doctors

www.analySEEs.co.uk 

6.

Promotional tools: Sample, PPM and gift (Pocket tissue / Money parts)

Campaign -02

1.

Objective: •

2.

To build five trustworthy prescribers of Ciprofloxacin powder for  suspension in each territory.

Activities: •



Special promotion highlighting the Pediatric typhoid and diarrhea to selective selective Pediatricians and GPs. Reminder promotion to make extra thirst to other target doctors.

3

Duration: May to August 2008

4.

Cycle Promotion

Promotion Detailing Reminder Gifts

Month May √ √

Jun √ √

July √ √

August √

5.

Target doctors:

Pediatricians General Practitioners Gynecologists Medicine specialists Gastroenterologists Internee Doctors

6.

Promotional tools: Sample, PPM and gifts (Pen / Coffee maker)

www.analySEEs.co.uk 

Campaign -03

1.

Objective: •

2.

To establish Ciprofloxacin as the drug of choice in the treatment tre atment of typhoid fever.

Activities: •

Special promotion highlighting typhoid fever to selective GPs.



Reminder promotion to make extra thirst to other target doctors

3

Duration: September to December 2008

4.

Cycle Promotion

Promotion Detailing Reminder Gifts 5.

Target doctors:

September √ √

Month October Nove November mber √ √ √ √

December  √

General Practitioners Gynecologists Medicine specialists Gastroenterologists Internee Doctors

6. Promotional tools: Sample and gifts (Liquid soap / Card holder / Tissue box)

www.analySEEs.co.uk 

8.0 Some Brands currently available in the global market

www.anal SEEs.co.uk 

www.analySEEs.co.uk 

 © Copyright 2008. Analysees Ltd, www.analysees.co.uk. All rights reserved. When quoting please cite “analySEEs.co.uk”. The above information does not constitute the provision of investment, legal or tax advice. Any views expressed reflect the current views of the author, which do not necessarily correspond to the opinions of Analysees Ltd or its affiliates. Opinions expressed may change without notice. Opinions expressed may differ from views set out in other documents, including research, published by Analysees Ltd. The above information is provided for informational purposes only and without any obligation, whether contractual or otherwise. No warranty or representation is made as to the correctness, completeness and accuracy of the information given or the assessments made

www.analySEEs.co.uk 

About analySEEs: It is an online based b outique analysis, strategic consultancy consultancy and business intellig intelligence ence firm f ocusi ocusing ng on qualitativ qualitative e research. We provide affordable and customised local market research, strategic and tactical recommendations. Our clients include retail and service businesses and the business-to-business sector. We help our clients achieve more by providing them with deep information on the companies, markets, and people that matter to them. We are working with experienced Research Professionals from different parts of the world. Our new move expanded us as far as South Asia and still we are growing with significant pace everyday. We offer a range of business services to organisations that are active in our specialist industries. So far our services include business research publications, customised research and business consulting.

www.analySEEs.co.uk 

Edited By: Mamun Ahmed & Thomas White

Contact

[email protected] www.analysees.co.uk

www.analySEEs.co.uk 

View more...

Comments

Copyright ©2017 KUPDF Inc.
SUPPORT KUPDF